End-stage liver disease and its complications are one of the most important global health problems particularly in Egypt due to the highest prevalence of chronic hepatitis C. liver transplantation is the only curative treatment but with high rate of complications and donor organ shortage. Stem cells are ''pluripotent'' cells that have the capacity to differentiate into any of the many different types of cells thus providing a potentially unlimited source of cells for medical and scientific purposes. Stem cell therapies for end-stage liver disease are under investigation all over the world. Induced pluripotent stem cells are artificially derived from adult somatic cells into an embryonic cell state by inducing a "forced" expression of specific genes. Disease specific human induced pluripotent stem cells, Drug toxicity screening and IPSCs banking are promising research goals for treatment of endstage liver disease. AIM OF THE ESSAY: The aim of this review is to get the latest data about the new methods of getting induced pluripotent stem cells (iPSCs), iPSCs banks and the potential clinical application in patients with liver disease.